Presbyterian Hospital of Dallas

Report presents U.S. perspective on biological drug indications and monitoring

Published in Hospital Law Weekly, January 5th, 2006

A researcher presents a U.S. perspective on biological drug indications and monitoring in a recent issue of the Annals of the Rheumatic Diseases.

According to a report from the United States, "An estimated 20% of patients with rheumatoid arthritis (RA) receive tumor necrosis factor (TNF) inhibitor treatment. This paper presents the results of an online survey of U.S. rheumatologists (1,023 respondents) conducted in April 2005 on issues relating to use of TNF inhibitors in RA."

"The primary determinant of TNF inhibitor use among the participating rheumatologists was physician preference rather than patient preference or payor guidelines....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Law Weekly

Source: Hospital Law Weekly (2006-01-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry